In vitro activities of voriconazole as a triazole derivative and caspofungin as an echinocandin were compared with those of some antifungal agents against Candida species isolated from clinical specimens

Japanese Journal of Infectious Diseases

Volumn 60, Issue 5, 2007, Pages 302-304

  Özçelik, Berrin ^a   Kaynak, Fatma ^a   Cesur, Salih ^b   Sipahi, Bilge ^a   Sultan, Nedim ^a  

^a GAZI UNIVERSITY   (Turkey)

^b Refik Saydam Hygiene Center   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; KETOCONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KEFYR; CANDIDA PARAPSILOSIS; CANDIDA SAKE; CANDIDA TROPICALIS; CONTROLLED STUDY; CULTURE MEDIUM; DILUTION; DRUG EFFICACY; DRUG SENSITIVITY; FUNGAL STRAIN; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPUTUM CULTURE; URINE CULTURE;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; SPUTUM; TRIAZOLES;

EID: 34948831097     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Özçelik, B. (2006): The evaluation of CHROMagar-Candida as an isolation medium for identification of Candida species isolated from different clinical specimens. Turkish J. Pharm. Sci., 3, 1.
2. National Committee for Clinical Laboratory Standards (1996): Reference method for broth dilution antifungal susceptibility testing yeast; approved standard. M27-A, 15, no.10, NCCLS, VA Medical Center, Tuscon.
3. Özçelik, B., Aslan, M., Orhan, I., et al. (2005): Antimicrobial and anti-viral activities of the lipophylic extracts of Pistacia vera L. Microbiol. Res., 160, 159-164.
4. Espinel-Ingroff, A., Boyle, K. and Sheehan, D.J. (2001): In vitro antifungal activities voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia, 150, 101-115.
5. Uzun, O., Arikan, S., Kocagöz, S., et al. (2000): Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish university hospital and effect of time of reading. Diagn. Microbiol. Infect. Dis., 38, 101-107.
6. Pfaller, M.A., Diekema, D.J., Meser, S.A., et al. (2003): Activities of fluconazole and voriconazole against 1586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion and E-test methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J. Clin. Microbiol., 41, 1440-1446.
7. Kucukates, E., Erturan, Z., Susever, S., et al. (2005): In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period. APMIS, 113, 278-283.
8. Özçelik, B., Çitak, S., Cesur, S., et al. (2004): In vitro susceptibility of Candida spp. to antifungal agents. Drug Metabol. Drug Interact., 20, 5-8.
9. Arikan, S., Sancak, B. and Hascelik, G. (2005): In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish university hospital. Med. Mycol., 43, 171-178.
10. Pawlitz, D., Young, M. and Klepser, M. (2003): Micafungin: a new echinocandin antifungal. Formulary, 38, 354-367.
11. Arora, D., Nguyen, M.H. and Clandy, C.J. (2005): Effect of concentrations exceeding minimum inhibitory concentrations of caspofungin on the selection of resistant strains of Candida spp. J. Undergrad. Res., 7, 1-7.
12. Pfaller, M.A., Diekema, D.J., Messer, S.A, et al. (2003): In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob. Agents Chemother., 47, 1068-1071.
13. Espinel-Ingroff, A. (1998): In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol., 36, 198-202.
14. McGinnis, M.R. and Rinaldi, M.G. (1991): Antifungal drugs: mechanism of action, drug resistance, susceptibility testing, and assays of activity in biological fluids. p. 198-257. In Lorian, V. (ed.), Antibiotics in Laboratory Medicine. Williams and Wilkins, Baltimore, Md.